Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 5 of 5 results for sitagliptin + metformin

  1. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA583

  2. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA336

  3. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 June 2014
    View recommendations

    Sections for TA315

  4. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 September 2013

  5. Insulin icodec for treating type 2 diabetes [ID6175]

    In development [GID-TA11104] Expected publication date: TBC

    Technology appraisal guidance
    In development